Beactica AB, the leading Swedish fragment-based drug discovery company, today announced a new investment and the addition of Innovationsbron AB to its shareholders. They join Uppsala University Holding Company and the founders as continuing investors. The funds will be used to finance the progression of Beactica’s internal drug discovery pipeline.

Beactica, the leading Swedish fragment-based drug discovery company, today announced the appointment of Professor Bo Öberg to its Board. Professor Öberg, CEO of Medivir HIV Franchise AB, brings almost 40 years of pharmaceutical industry experience as a senior executive and board member in both biotechnology and pharmaceutical companies.